-
Value-Based Assessment of Trifluridine Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Sep 9, 2025, 16:22 PM -
Intra-Procedure Cost Variability: A Retrospective Analysis of Real-World Patient Level Information Costing (PLICS) Data for a Minimally Invasive BPO Therapy in the NHS
Sep 9, 2025, 16:22 PM -
Impacts of National Medical Insurance Negotiation on Antitumor Drug Utilization and Financial Burden: A City-Level Analysis in China
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model
Sep 9, 2025, 16:22 PM -
Population-Level Impact Assessment of the Revised Dyslipidemia Prescription Protocol in Greece Using Simulation Modeling
Sep 9, 2025, 16:22 PM -
Mapping PBS Drug Pathways in Australia: A Framework and Interactive Tool for Category-Specific Pricing Calculations
Sep 9, 2025, 16:22 PM -
Measurement Properties of the EQ-5D in Hematological Cancers: A Systematic Review
Sep 9, 2025, 16:22 PM -
Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany
Sep 9, 2025, 16:22 PM -
Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States
Sep 9, 2025, 16:22 PM -
The Fiscal Case for Investing in COVID-19 Vaccination: A UK Treasury Perspective
Sep 9, 2025, 16:22 PM -
Estimating the Public Health and Economic Impact of Recombinant Zoster Vaccine (RZV) Vaccination for Adults Aged 50 and Older in South Korea
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and France: Lessons for Poland
Sep 9, 2025, 16:22 PM -
Potential Operational Efficiencies of a Combination Influenza and COVID-19 Vaccine in US Pharmacies
Sep 9, 2025, 16:22 PM -
Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High-Efficacy Disease-Modifying Therapy in Mexico
Sep 9, 2025, 16:22 PM -
Proportion of the Expenses of Over-the-Counter Equivalent Drugs Among Total Healthcare an Analysis Using the Wellness-Star☆ Database
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
Bimekizumab Budget Impact Analysis for the Treatment of Patients With Moderate-to-Severe Hidradenitis Suppurativa (HS) in Greece
Sep 9, 2025, 16:22 PM -
Graphical Evidence Frameworks to Visualize the Holistic Value of Healthcare Interventions
Sep 9, 2025, 16:22 PM -
Describing the Real-World Burden of Demodex Blepharitis: A Multicenter Audit in a UK Public Specialist Eye-Care Setting
Sep 9, 2025, 16:22 PM -
Preliminary Real-World Results of a Community Pharmacy-Based Intervention in COPD: Evidence From the Chronic Diseases From A to Z Program
Sep 9, 2025, 16:22 PM
